Loading
Ocular Therapeutix, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Feb 2026.
Ocular Therapeutix, Inc: what insiders have been doing
Every trade that managers of Ocular Therapeutix, Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 18 insiders published 50 filings.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €392k) and 23 sales (8 insiders, €2.6M). Netting one side against the other leaves €2.2M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a sale of €951k by Dugel Pravin, published on 17 February 2026. On the buying side, the filings list 1 senior executive among the declarants.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 50 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 17 purchases and 61 sales. The 10-K for the year ended 31 December 2025 shows 52.0 m USD of revenue and -265.9 m USD of net income.
The last insider purchase was made public on 24 February 2026, 236 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
160
Thresholds
n/a
Buy Volume
€13M
17 ops. · all time
Sell Volume
€5M
61 ops. · all time
Who traded when
BuySaleJeffrey S. Heier9 sales
Peter Kaiser9 sales
Pravin Dugel9 sales
Sanjay Nayak8 sales
Notman Donald4 sales
Waheed Nadia3 sales
+3 other insiders
Since the insiders bought
- -12.7%Entry US$9.50 · Close at T+90 US$8.29
- +12.1%Entry US$5.28 · Close at T+365 US$5.92
- -47.5%Entry US$10.56 · Close at T+365 US$5.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ocular Therapeutix, Inc Strong Buy (bullish), based on 12 analysts. Average price target: US$26.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,288 of 24,148 companies
31.0
score / 100
Value13
Quality49
FCF yld-13%
Earn yld-16%
EV/EBITDA·
ROE-73%
Gross mgn87%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.56
Analyst consensus
12 analystsStrong buy
US$14.00Target US$26.00(+244%)US$34.00
Income statement
RevenueUS$52M
Gross profitUS$45.4M87% margin
EBITDA-US$249.8M-481% margin
Net income-US$265.9M-511.9% margin
Valuation
PER (forward)-5.1x
P/Book3.2x
Beta0.99
Balance sheet & cash
Market capUS$1.7B
Total debtUS$77M
Free Cash Flow-US$216.9M
Debt / Equity15%
Profitability & ownership
ROE-73.0%
ROA-35.0%
% insiders0.9%
% institutions95.3%
Last declaration on 13 October 2026
Declarations160 total
11,984 shares@ US$7.29Common StockSEC:0001104659-26-115551:0
11,984 shares@ US$7.286100.0% of flowCommonSEC144:0001950047-26-010123
9,990 shares@ US$7.050.0035% mcap24.6% of flowCommon StockSEC:0001104659-26-114081:0
10,869 shares@ US$7.050.0038% mcap24.7% of flowCommon StockSEC:0001104659-26-114080:0
10,869 shares@ US$7.051269.2% of flowCommonSEC144:0001950047-26-009997
9,990 shares@ US$7.05369.1% of flowCommonSEC144:0001950047-26-009999
1,099 shares@ US$10.23830.0007% mcap100.0% of flowCommonSEC144:0001950047-26-008839
50,092 shares0Common StockSEC:0001104659-26-101667:1
21,649 shares@ US$10.770.011% mcap21.0% of flowCommon StockSEC:0001104659-26-101667:0
50,092 shares0Common StockSEC:0001104659-26-101667:2
3,296 shares@ US$10.780.0016% mcap25.4% of flowCommon StockSEC:0001104659-26-101670:0
3,035 shares@ US$10.770.0015% mcap38.5% of flowCommon StockSEC:0001104659-26-101674:0
1,897 shares@ US$10.780.0009% mcap24.1% of flowCommon StockSEC:0001104659-26-101671:0
3,296 shares@ US$10.78040.0021% mcap100.0% of flowCommonSEC144:0001950047-26-008628
21,649 shares@ US$10.77120.014% mcap100.0% of flowCommonSEC144:0001950047-26-008629
3,035 shares@ US$10.77490.0020% mcap100.0% of flowCommonSEC144:0001950047-26-008627
1,897 shares@ US$10.78160.0012% mcap100.0% of flowCommonSEC144:0001950047-26-008630
50,092 sharesCommon StockSEC:0001104659-26-075709:0
50,092 sharesCommon StockSEC:0001104659-26-075709:1
14,828 shares@ US$8.2714100.0% of flowCommonSEC144:0001950047-26-005548
21,156 shares@ US$8.200.0074% mcap15.7% of flowCommon StockSEC:0001104659-26-067485:0
394,696 shares0Common StockSEC:0001104659-26-067485:1
394,696 shares0Common StockSEC:0001104659-26-067485:2
394,696 shares0Common StockSEC:0001104659-26-042694:0
394,696 shares0Common StockSEC:0001104659-26-042694:1
25 of 160 declarations
About Ocular Therapeutix, Inc
Ocular Therapeutix, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ, with a core focus on ophthalmology and, in particular, retinal disease. The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Its strategy is built around a proprietary bioresorbable hydrogel platform designed to deliver therapeutic agents locally and in a programmed manner within the eye. That platform approach is important competitively: in eye care, longer durability, better adherence, and fewer repeat procedures can be clinically meaningful and commercially attractive, especially in retinal diseases where treatment burden is a major issue.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465924054052/tm248018d2_ars.pdf))
Ocular’s commercial anchor is DEXTENZA, an intracanalicular dexamethasone insert used in the United States for the treatment of post-surgical ocular inflammation and pain, as well as ocular itching associated with allergic conjunctivitis. Current revenue is largely generated through DEXTENZA sales to specialty distributors and through direct sales to certain ambulatory surgery centers and physicians’ offices. While this commercial base is still relatively small compared with large ophthalmology franchises, it gives the company an approved product, operating experience in the U.S. market, and a revenue stream that supports ongoing development efforts.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465924054052/tm248018d2_ars.pdf))
Read moreShow less
The key value driver is AXPAXLI, also known as OTX-TKI, Ocular’s intravitreal axitinib implant for retinal disorders, with wet age-related macular degeneration (wet AMD) as the lead indication. In 2026, the company reported that the SOL-1 Phase 3 trial had delivered superiority results with materially fewer rescue treatments than single-dose aflibercept, and management said it was preparing for an NDA submission subject to ongoing discussions with the U.S. FDA. Ocular also stated that SOL-R continues to progress, with topline data expected in the first quarter of 2027. Beyond these late-stage programs, the company maintains additional development assets at earlier stages, underscoring a broader pipeline strategy rather than reliance on a single asset.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm))
Geographically, Ocular’s commercial activity remains primarily U.S.-focused, although it has licensing arrangements covering parts of Asia through AffaMed Therapeutics for selected products. The company’s Bedford site includes manufacturing, laboratory, warehouse and office space, and it has disclosed a future corporate headquarters on the same campus. From a financial standpoint, Ocular is still a development-heavy biotech, but it strengthened its balance sheet through a sizable 2025 equity raise. Recent milestones include positive late-stage clinical execution, continued advancement of its retina franchise, and preparations for a potential future commercial launch of AXPAXLI if regulatory discussions progress favorably.([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm))
